摘要
Objective： To observe the effect of Xueyou Mixture （血友合剂, XYM） on blood coagulation factors and its safety in treating hemophilia. Metheds： To the randomly selected 65 inpatients of hemophilia, XYM was administered accompanied with intravenous dripping of liver cell growth factor 60-100 mg once a day to protect the liver, with no blood products like concentrated ／~ and FIX factors or blood plasma given. The treatment lasted for 3 weeks. The short-term efficacy and adverse reactions were observed. The long-term efficacy in patients was observed in a follow-up study of 6-12 months after they were discharged from the hospital but continuously took XYM orally. Results： The short-term markedly effective rate in the patients was 95.38% （62/65）. After they were treated for 3 weeks, the level of FⅧ factor activity increased in 56 patients of type A from （3.32 ± 2.21） % to （4.18± 2.23） %, and in 9 of type B from （4.92 ± 1.81） % to （5.64± 1.96） %. Compared with that before treatment, the difference was significant in both of them （P〈0.01）. No obvious adverse reaction was found in the treatment period. The follow-up study showed that in 22 patients of type A, the FⅧ factor activity ratio increased from （3.25±2.11） % to （6.31 ±2.16） %, （8.36±1.05） %, and （16.38±2.71） % in the 2nd, 3rd and 6th month after discharge respectively, all showing significant difference to that before treatment （P〈0.01）; and in 4 patients of type B, it increased from （4.15±2.26） % to 7.8% and 11.6% （mean value） in the 2nd and 6th month respectively. Conclusion： XYM could raise the activity of factors Ⅷ and Ⅸ in patients with hemophilia, and the degree of the rise is related with the duration of the therapy, with no obvious adverse reaction, which strikes out a new path and new train of thinking for the treatment of the disease by nonblood preparation.
Objective： To observe the effect of Xueyou Mixture （血友合剂, XYM） on blood coagulation factors and its safety in treating hemophilia. Metheds： To the randomly selected 65 inpatients of hemophilia, XYM was administered accompanied with intravenous dripping of liver cell growth factor 60-100 mg once a day to protect the liver, with no blood products like concentrated ／~ and FIX factors or blood plasma given. The treatment lasted for 3 weeks. The short-term efficacy and adverse reactions were observed. The long-term efficacy in patients was observed in a follow-up study of 6-12 months after they were discharged from the hospital but continuously took XYM orally. Results： The short-term markedly effective rate in the patients was 95.38% （62/65）. After they were treated for 3 weeks, the level of FⅧ factor activity increased in 56 patients of type A from （3.32 ± 2.21） % to （4.18± 2.23） %, and in 9 of type B from （4.92 ± 1.81） % to （5.64± 1.96） %. Compared with that before treatment, the difference was significant in both of them （P〈0.01）. No obvious adverse reaction was found in the treatment period. The follow-up study showed that in 22 patients of type A, the FⅧ factor activity ratio increased from （3.25±2.11） % to （6.31 ±2.16） %, （8.36±1.05） %, and （16.38±2.71） % in the 2nd, 3rd and 6th month after discharge respectively, all showing significant difference to that before treatment （P〈0.01）; and in 4 patients of type B, it increased from （4.15±2.26） % to 7.8% and 11.6% （mean value） in the 2nd and 6th month respectively. Conclusion： XYM could raise the activity of factors Ⅷ and Ⅸ in patients with hemophilia, and the degree of the rise is related with the duration of the therapy, with no obvious adverse reaction, which strikes out a new path and new train of thinking for the treatment of the disease by nonblood preparation.
